Tempus AI (NASDAQ:TEM) has been on fire, drawing massive interest from institutional investors in the fourth quarter of 2024 as big funds piled into the AI-powered precision medicine company.
Since going public in June 2024, Tempus has quickly become a favorite among investors. The number of institutional filings jumped from 89 to 174 in just three quarters, and the total number of shares heldexcluding optionshas climbed significantly.
Cathie Wood's ARK Investment Management was one of the most aggressive buyers, boosting its stake by 132% from Q3 and an eye-popping 956% from Q2, bringing its holdings to $186.3 million. JPMorgan Chase (NYSE:JPM) made an even bigger move, adding 1,650,096 sharesa staggering 43424% increase in just one quarter. UBS Group (NYSE:UBS) wasn't far behind, increasing its stake by 6524% (786,025 shares).
And they weren't the only ones. Barclays (NYSE:BCS) raised its position by 3675%, while Goldman Sachs (NYSE:GS) and Morgan Stanley (NYSE:MS) increased theirs by 129% and 40%, respectively. Meanwhile, BlackRock (NYSE:BLK), Bank of New York Mellon (NYSE:BK), and Ken Griffin's Citadel Advisors all took fresh positions, joining 70 other funds in making a big bet on Tempus AI.
This article first appeared on GuruFocus.免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。